Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4-Reference-Cited by-同舟云学术

Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4

Published:2016-08-11 Issue:10 Volume:65 Page:1177-1188
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Lopez Marc,Ghidouche Abderrezak,Rochas Caroline,Godelaine Danièle,Carrasco Javier,Colau Didier,Hames Gérald,Montero-Julian Félix A.,Coulie Pierre G.,Olive Daniel

Funder

Ligue Contre le Cancer (FR)

INCA

Fondation contre le cancer

Institut Paoli-Calmettes

INSERM

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1877-7.pdf

Reference42 articles.

1. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341(6151):1192–1198

2. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135–146

3. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, Finetti P, Sauvan R, Adelaide J, Geneix J, Lecocq E, Popovici C, Dubreuil P, Viens P, Goncalves A, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Lopez M (2007) Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 7:73

4. Reymond N, Fabre S, Lecocq E, Adelaide J, Dubreuil P, Lopez M (2001) Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem 276(46):43205–43215

5. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280(20):19543–19550

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

2. Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens;International Journal of Molecular Sciences;2023-01-24

3. Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms;Pharmaceutics;2022-07-11

4. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab;Clinical and Translational Oncology;2021-10-23

5. Chimeric Antigen Receptors for the Tumour Microenvironment;Advances in Experimental Medicine and Biology;2020